Pyxis Oncology’s (PYXS) Buy Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.08) EPS, Q1 2027 earnings at ($0.18) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.35) EPS, FY2029 earnings at $0.23 EPS and FY2030 earnings at $0.76 EPS.

A number of other research firms have also commented on PYXS. Weiss Ratings lowered Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company started coverage on Pyxis Oncology in a research report on Monday, August 3rd. They set an “overweight” rating and a $12.00 price objective for the company. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Leerink Partners reduced their target price on Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Finally, Wedbush initiated coverage on Pyxis Oncology in a report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

View Our Latest Analysis on Pyxis Oncology

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $3.12 on Tuesday. Pyxis Oncology has a 52 week low of $1.03 and a 52 week high of $5.55. The firm has a market cap of $197.65 million, a PE ratio of -2.21 and a beta of 1.31. The firm’s fifty day moving average is $2.67 and its 200-day moving average is $2.02.

Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Sell-side analysts forecast that Pyxis Oncology will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in PYXS. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $25,000. Fox Run Management L.L.C. bought a new stake in shares of Pyxis Oncology in the 4th quarter valued at $26,000. Engineers Gate Manager LP acquired a new position in shares of Pyxis Oncology during the 4th quarter valued at $26,000. LPL Financial LLC lifted its position in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after acquiring an additional 21,100 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Pyxis Oncology during the 2nd quarter valued at $40,000. 39.07% of the stock is owned by institutional investors and hedge funds.

Key Pyxis Oncology News

Here are the key news stories impacting Pyxis Oncology this week:

  • Positive Sentiment: HC Wainwright raised its EPS forecasts across several periods, including FY2026 to a loss of $1.08 from $1.10, FY2027 to a loss of $0.73 from $0.88, and FY2028 to a loss of $0.35 from $0.44. The firm also improved estimates for multiple 2027 quarters and now projects positive EPS of $0.23 in FY2029, up from $0.20. These revisions suggest expectations for narrower losses and a faster path toward profitability.
  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $7.00 price target for Pyxis Oncology (PYXS). The target implies substantial upside from recent trading levels and may provide support for investor sentiment. HC Wainwright Reaffirms Buy Rating for Pyxis Oncology
  • Neutral Sentiment: The favorable revisions are concentrated in one analyst’s model rather than representing new clinical, regulatory, or partnership news. Investors may therefore view the update as a valuation opinion instead of a fundamental business catalyst.
  • Negative Sentiment: HC Wainwright slightly reduced its FY2030 EPS forecast to $0.76 from $0.77. Although the change is minor, Pyxis Oncology continues to forecast losses through FY2028 in the firm’s model, underscoring the company’s ongoing cash-burn and execution risks.

Pyxis Oncology Company Profile

(Get Free Report)

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

Read More